Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening
Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026
Regulatory News:
